Myogen Compound definition

Myogen Compound shall have the meaning set forth in Section 1.22 of the Collaboration Agreement.
View Source
Myogen Compound means any Active Compound that is Controlled by Myogen and is identified and/or synthesized by Myogen, its Affiliates, and/or its external academic collaborators in the Field, except for any Active Compound that has therapeutic action against both a Myogen Target and Targets within Myogen's HDAC inhibitor program.
View Source
Myogen Compound shall have the meaning set forth in the Collaboration Agreement.
View Source

Examples of Myogen Compound in a sentence

  • In the event that a Myogen Compound, Collaboration Compound or NIBRI Compound fails in development, any milestone payments previously paid with respect to such Myogen Compound, Collaboration Compound or NIBRI Compound shall be fully creditable toward the same milestone due with respect to another Myogen Compound, Collaboration Compound or NIBRI Compound advanced as a lead Compound in place of the failed Compound that acts on the same Myogen Target or Collaboration Target.

  • Except as explicitly set forth below, milestone payments shall be payable only once with respect to a particular Myogen Compound, Collaboration Compound or NIBRI Compound, even though that Myogen Compound, Collaboration Compound or NIBRI Compound may be subsequently developed for indications other than those for which regulatory approval was initially sought.

  • Except as disclosed in writing between the parties to this Agreement or their respective agents, as of the Effective Date, to Myogen's knowledge there are no issued patents or pending patent applications that, if issued, would be infringed by the development, manufacture, use or sale of any Myogen Compound or Myogen Target, as applicable, pursuant to this Agreement.

  • In addition, NIBRI agrees that, during the term of this Agreement and after termination of this Agreement, NIBRI and its Affiliates will not develop and/or commercialize (either by themselves or through a Third Party) a compound that is a Myogen Compound except in the Field under a License Agreement.

  • Except as explicitly set forth below, pre-clinical milestone payments shall be payable on only one Active Compound per Myogen Target or Collaboration Target and clinical milestone payments shall be payable only once with respect to a particular Myogen Compound, Collaboration Compound or NIBRI Compound, even though that Myogen Compound, Collaboration Compound or NIBRI Compound may be subsequently developed for indications other than those for which regulatory approval was initially sought.

  • Subject solely to the terms of this Agreement and any License Agreement executed by the Parties, NIBRI hereby grants to Myogen and its Affiliates a fully paid, exclusive, royalty-free, perpetual, world-wide license to use, have used, develop, make, manufacture and sell all Myogen Compounds outside of the Field and, after expiration of NIBRI’s Option with respect to any such Myogen Compound, inside the Field.

  • Except as disclosed in writing between the parties to this Agreement or their respective agents, as of the Effective Date, to Myogen’s knowledge there are no issued patents or pending patent applications that, if issued, would be infringed by the development, manufacture, use or sale of any Myogen Compound or Myogen Target, as applicable, pursuant to this Agreement.


More Definitions of Myogen Compound

Myogen Compound means any Active Compound that is Controlled by Myogen and is identified and/or synthesized by Myogen, its Affiliates, and/or its external academic collaborators in the Field (or, if applicable, by the licensor or assignor to Myogen or its Affiliates if the rights to such compound were licensed to or acquired by Myogen or its Affiliates), including, as of the Amendment Date, any HDAC Inhibitor Compounds but excluding any NIBRI HDAC Inhibitor Compound.
View Source
Myogen Compound means any compound (i) Controlled by Myogen, its Affiliates, and/or its external academic collaborators (or, if applicable, by the licensor or assignor to Myogen or its Affiliates if the rights to such compound were licensed to or acquired by Myogen or its Affiliates) and all enantiomers, racemate(s), isomers, diastereomers, active metabolites and pharmaceutically acceptable salt or complex thereof and any Active Moiety, analog or derivative of such Myogen Compound or the foregoing, and (ii) with respect to which NIBRI’s Head of CV Chemistry or his designee consented to the contribution of such compound to the collaboration. If such consent is not given, such compounds shall remain outside of the collaboration. For the avoidance of doubt, the parties acknowledge that NIBRI or one or more of its employees, agents or Affiliates previously contented to the contribution of certain dihydrotheino pyridine compounds to the collaboration and that such compounds and all derivatives and analogs thereof are Myogen Compounds.
View Source

Related to Myogen Compound

  • Licensed Compound means [***].

  • Collaboration Compound means any of the following: (a) FG-4592, (b) any HIF Compound (other than FG-4592) that is added to this Agreement pursuant to Section 3.6, and (c) any salts, esters, complexes, chelates, crystalline and amorphous morphic forms, pegylated forms, enantiomers (excluding regioisomers), prodrugs, solvates, metabolites and catabolites of any of the foregoing ((a) or (b)).

  • Back-Up Compound means, with reference to any particular Development Candidate or Drug Product Candidate, a Compound which (a) has the same principal mode of action (i.e., Potentiator or Corrector) as that Development Candidate or Drug Product Candidate; and (b) was among the group of Compounds, identified by VERTEX as potential additional lead molecules having the same principal mode of action, from which the Development Candidate was selected.

  • Lead Compound means any compound of lead other than galena which, when treated in the manner described below, yields to an aqueous solution of hydrochloric acid, a quantity of soluble lead compound exceeding, when calculated as lead monoxide, five per cent of the “dry weight” of the portion taken for analysis. In the case of paints and similar products and other mixtures containing oil or fat the “dry weight” means the dry weight of the material remaining after the substance has been thoroughly mixed and treated with suitable solvents to remove oil, fats, varnish or other media.

  • Licensed Compounds means: (a) Research Program Active Compounds; (b) Novartis Active Compounds; (c) salts, hydrates, solvates, esters, metabolites, intermediates, stereoisomers and polymorphs of Research Program Active Compounds or Novartis Active Compounds; and (d) prodrugs of Research Program Active Compounds or Novartis Active Compounds (any of the foregoing, a “Licensed Compound”).